Nov 6 |
Inhaled Heparin reduces COVID-19 risk: real-time meta analysis of 3 studies | |
| Significantly lower risk is seen for mortality, ventilation, and hospitalization. One study shows significant benefit. Meta analysis using the most serious outcome reported shows 50% [17‑70%] lower risk. Currently all studies a.. | ||
Oct 31 |
et al., eClinicalMedicine, doi:10.1016/j.eclinm.2025.103339 | Efficacy of inhaled nebulised unfractionated heparin to prevent intubation or death in hospitalised patients with COVID-19: an investigator-initiated international meta-trial of randomised clinical studies |
| 58% lower mortality (p=0.01), 47% lower ventilation (p=0.01), and 23% lower hospitalization (p=0.02). Meta-trial of 6 RCTs with 478 hospitalized COVID-19 patients showing significant benefit with inhaled nebulized unfractionated heparin (UFH). Patients receiving nebulized UFH had lower rates of intubation or death at longest follow-up (11.. | ||
Mar 27 |
et al., Anaesthesia and Intensive Care, doi:10.1177/0310057X251322783 | A randomised, open-label trial of nebulised unfractionated heparin in patients mechanically ventilated for COVID-19 |
| 70% higher mortality (p=1). RCT 50 intubated COVID-19 patients showing no improvement with inhaled nebulized unfractionated heparin. Time to separation from invasive ventilation among survivors to day 28 was significantly slower in the heparin group. | ||
Jun 30 2023 |
et al., Pulmonary Pharmacology & Therapeutics, doi:10.1016/j.pupt.2023.102212 | Inhaled nebulised unfractionated heparin (UFH) for the treatment of hospitalised patients with COVID-19: A randomised controlled pilot study |
| 42% lower mortality (p=0.27), 42% lower ventilation (p=0.27), and 5% shorter hospitalization (p=0.8). RCT 75 hospitalized patients with COVID-19 showing reduced mortality with inhaled nebulized unfractionated heparin (UFH). | ||
Please send us corrections, updates, or comments.
c19early involves the extraction of 200,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. IMA and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.